C12N 2710/22071
Demonstrated in vivo effect
C12N2710/22071 (Demonstrated in vivo effect) appears on 4 US grants and 11 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 11
- Assignees
- 6
- Inventors
- 15
- Latest grant
- 5 Apr 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 1 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 2 |
| 2019 | 1 | 2 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Drug delivery system based on JCV-VLP5 Apr 2022US 11,291,735 B2Life Science Inkubator Betriebs GmbH & Co. KG
- Method for augmenting vision in persons suffering from photoreceptor cell degeneration16 Apr 2019US 10,259,857 B2The General Hospital Corporation
- Polyoma virus JC peptides and proteins in vaccination and diagnostic applications22 Aug 2017US 9,738,690 B2Universitaet Zuerich
- Method for augmenting vision in persons suffering from photoreceptor cell degeneration6 Sep 2016US 9,434,781 B2The General Hospital Corporation
- Therapeutic nucleic acids, peptides and uses i12 Jun 2025US 2025/0188137 A1
- Active delivery of nucleic acids and peptides, methods and uses31 Aug 2023US 2023/0270887 A1
- Therapeutic nucleic acids, peptides and uses ii31 Aug 2023US 2023/0272022 A1
- Method for augmenting vision in persons suffering from photoreceptor cell degeneration29 Aug 2019US 2019/0263883 A1The General Hospital Corporation
- Novel drug delivery system based on jcv-vlp4 Jul 2019US 2019/0201549 A1Life Science Inkubator Betriebs GmbH & Co. KG
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.